BACKGROUND The value of routine administration of intravenous thrombolytic agents during percutaneous transluminal coronary angioplasty (PTCA) therapy of acute myocardial infarction (MI) has not been determined. Therefore, we prospectively randomized 122 patients with evolving MI to PTCA therapy with or without adjunctive intravenous streptokinase therapy. METHODS AND RESULTS Patients with EC...

BACKGROUND Intrapleural fibrinolytic agents are used in the drainage of infected pleural-fluid collections. This use is based on small trials that did not have the statistical power to evaluate accurately important clinical outcomes, including safety. We conducted a trial to clarify the therapeutic role of intrapleural streptokinase. METHODS In this double-blind trial, 454 patients with pleur...

OBJECTIVE To determine whether (1) a decreased concentration of Lactobacilli allows S. pyogenes to grow; (2) S. pyogenes is able to grow in the presence of healthy Lactobacillus concentrations; (3) S. pyogenes is capable of inhibiting Lactobacilli. METHODS One hundred fifty patient samples of S. pyogenes were mixed with four different concentrations of L. crispatus and L. jensenii. Colony cou...

adverse reactions of streptokinase in patients with or without hydrocortisone injection nasiri m*1 , rahimian b2, bashiri t 3, salmalian f4 received: 25 april, 2010 accepted: 27 july, 2010 abstract background & aims: streptokinase is one of the most useful drugs in acute myocardial infarction. researches show that timely given injection of streptokinase decreases total mortality. allergic react...

OBJECTIVE To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction. DESIGN Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay. SETTING Coronary...

BACKGROUND The optimal dose of Streptokinase in the treatment of acute myocardial infarction is not well established. Apparently, the thrombolytic efficacy would not increase with doses over 750,000 units. AIM To compare the effectiveness and safety of treatment with low doses of Streptokinase, ranging from 500,000 to 750,000 units, in patients with ST elevation acute myocardial infarction. ...

The work was aimed at the observation of the incidence and course of environmental mastitis in the breeding with a mean number of 177 dairy cows free housed and milked in the milking parlour after introduction of anti-mastitis measures. During 6 months of application of preventive inhibitory methods the incidence of bacteriological positive dairy cows was reduced from 72.99 % to 6.74 %, and occ...

BACKGROUND Empyema thoracis in children causes significant morbidity. Standard treatment of Empyema thoracis includes tube drainage and antibiotics. But the tube drainage often fails. Intrapleural Streptokinase has been used in empyema thoracis with good success rate. OBJECTIVES We evaluated the efficacy of intra-pleural Streptokinase in management of empyema thoracis even in advanced stages....

OBJECTIVE To examine early leucocyte responses and neutrophil activation in acute myocardial infarction treated by streptokinase and to relate the findings to coronary recanalisation and indices of myocardial damage in order to provide further information about the role of neutrophils in the evolution of injury. DESIGN Group analysis of paired blood samples, obtained before streptokinase trea...

BACKGROUND Worldwide, streptokinase remains the most used thrombolytic agent for the treatment of myocardial infarction. Recombinant streptokinase, from E. coli, is increasingly used in developing countries as a biosimilar of native streptokinase; however, potency assignments relative to the WHO International Standard (IS) are highly variable with potentially dangerous consequences. A proportio...